(2010). A new isoquinolinium derivative, Cadein1, preferentially induces apoptosis in p53-defective cancer cells with functional mismatch repair via a p38-dependent pathway.
(2001). A: Function and interactions of integrins. Cell Tissue Res
(2000). Betagalactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin.
(2006). C: beta1-integrinmediated signaling essentially contributes to cell survival after radiationinduced genotoxic injury. Oncogene
(2005). Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord
(2005). CC: Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecologic oncology
(2007). Chung SH: Overexpression of BACE1 stimulates spontaneous basal secretion in PC12 cells. Neuroscience letters
(1977). Concomitant elevations in serum sialytransferase activity and sialic acid content in rats with metastasizing mammary tumors.
(1978). Elevated serum cathepsin B1 and vaginal pathology after prenatal DES exposure. Obstetrics and gynecology
(1990). Elucidation of sialyltransferase as a tumour marker.
(1999). et al: Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE.
(2000). Ganguly A: Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma
(1986). Golgi and secreted galactosyltransferase. CRC critical reviews in biochemistry
(1995). High alpha-2,6-sialylation of N-acetyllactosamine sequences in ras-transformed rat fibroblasts correlates with high invasive potential. Glycobiology
(2002). Ionizing radiation induces up-regulation of functional beta1-integrin in human lung tumour cell lines in vitro.
(1988). JC: The role of a cathepsin D-like activity in the release of Gal beta 1-4GlcNAc alpha 2-6-sialyltransferase from rat liver Golgi membranes during the acute-phase response. The Biochemical journal
(1993). Kemmner W: Enhanced activity of CMPneuAc: Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer letters
(2007). Kitazume S: Beta-galactoside alpha2,6-sialyltransferase I cleavage by BACE1 enhances the sialylation of soluble glycoproteins. A novel regulatory mechanism for alpha2,6-sialylation. The Journal of biological chemistry
(2009). Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo. Glycobiology
(2001). On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev
(2007). Park CC: beta1 integrin as a molecular therapeutic target.
(2005). PJ: Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.
(2004). Saido TC, Hashimoto Y: Involvement of proteases in glycosyltransferase secretion: Alzheimer’s beta-secretase-dependent cleavage and a following processing by an aminopeptidase. Glycoconjugate journal
(1982). Serum sialyl transferase levels in patients with metastatic breast cancer treated by chemotherapy. British journal of cancer
(1980). Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. Journal of surgical oncology
(1979). Sialyl transferase activity: a serum enzyme marker in the follow-up of cancer patients. Recent results in cancer research. Fortschritte der Krebsforschung
(1979). Sialyltransferase levels and sialic acid concentrations in sera of patients with malignant melanomas. Archives of dermatological research
(2005). SL: A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering beta1 integrin sialylation.
(2005). SL: Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res
(2002). SL: Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors.
(2007). Steelant WF: Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
(2008). Taniguchi N: Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer science
(2000). The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role.
(1996). Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer research
(2009). Wong PC: The beta-secretase enzyme BACE in health and Alzheimer’s disease: regulation, cell biology, function, and therapeutic potential.
(2009). Y: Development of sandwich enzyme-linked immunosorbent assay systems for plasma beta-galactoside alpha2,6-sialyltransferase, a possible hepatic disease biomarker. Analytica chimica acta
(2010). YS: Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation. Oncol Rep
(2008). YS: Protein sialylation by sialyltransferase involves radiation resistance. Mol Cancer Res
(2010). YS: Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells.